Arrow Capital’s Novo Nordisk NVO Stock Holding History

Arrow Capital’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-100,000	Closed	-$4.79M	–	29
2026 Q2	$4.79M	Buy	+100,000	New	+$4.3M	4.08%	11
2026 Q1	–	Sell	-130,000	Closed	-$6.61M	–	25
2025 Q4	$6.61M	Buy	130,000 +60,000	+86%	+$3.07M	6.34%	8
2025 Q3	$5.87M	Buy	+70,000	New	+$4.1M	3.15%	20
2025 Q1	–	Sell	-30,000	Closed	-$2.58M	–	37
2024 Q4	$2.58M	Buy	+30,000	New	+$3.24M	2.36%	21

Other funds holding NVO

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Everett Harris & Co Los Angeles, California $8.46B AUM 13.48% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Saratoga Research & Investment Management Saratoga, California $1.82B AUM 11.8% 1-Year Est. Return

Markel Group Glen Allen, Virginia $12.8B AUM 8.77% 1-Year Est. Return

Natixis Paris, France $28B AUM 27.03% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Oppenheimer Asset Management New York $9.5B AUM 23.46% 1-Year Est. Return

Arrow Capital's NVO Position: Q3 2026 in Review

Arrow Capital sold out of Novo Nordisk (NVO) in Q3 2026, closing a stake of 100,000 shares — an estimated $4.79M sold.

Arrow Capital first reported a position in NVO in Q4 2024 and held it in 4 quarters. The position peaked at $6.61M in Q4 2025. 696 funds tracked by Wall St. Rank hold NVO as of Q3 2026.

Arrow Capital reported no remaining Novo Nordisk position as of Q3 2026 after selling out during the quarter.
Arrow Capital sold 100,000 Novo Nordisk shares in Q3 2026, an estimated $4.79M.
Arrow Capital first reported a position in Novo Nordisk in Q4 2024 and held it in 4 quarters.
Arrow Capital's Novo Nordisk position peaked at $6.61M in Q4 2025.
696 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.

Based on Arrow Capital's 13F filing for Q3 2026, filed 6 Nov 2026.